How The Marijuana Market is Surprisingly Similar to The Tech Industry

The cannabis market has managed to remain incredibly lucrative over the course of the past several years, but with the advent of legalization and the changing public sentiment, it seems as though the market may just be getting started.

As far as the federal government is concerned, marijuana is still scheduled as a Schedule I narcotic, meaning that it has no potential for medicinal use as well as a high rate of addiction. Both of these claims have been widely refuted throughout the past several years by various medical professionals and scientific journals, thus the need for new laws and regulations.

According to one report “The cannabis plant produces more than 100 compounds (called cannabinoids), though most people know about just one. THC, short for tetrahydrocannabinol, is the psychoactive component that gets the user high. That is the drug that launched a counter-culture and the government campaign against it. It is also the recreational component.” A large amount of research is currently being conducted on one of the most important chemicals within the plant, CBD. CBD or cannabidiol has been hailed as having more potential to treat diseases than most other drugs currently on the market. CBD is also a non-psychoactive component of the plant, which in other words means that it does not get the user high. This is especially helpful in cases dealing with children, as the more mild the drug, the better.

Both of these compounds work individually, but they do have more of an effect when working with one another. Scientists have been working on creating a new series of drugs using the chemical CBD. In recent news, a new drug using components from the cannabis plant is scheduled to be voted on by the Food and Drug Administration in the U.S. to determine whether or not it should be allowed. The FDA has shown a considerable amount of positivity in terms of this new drug given how much potential it has shown to treat seizures in young children caused by a variety of illnesses. The drug is known as Epidiolex and is scheduled to be reviewed sometime in the near future.

Todd Harrison, founder, and CIO of CB1 Capital, a company that works within the marijuana industry stated recently that “legal weed, as some call it, has the wrong connotation. Tomorrow’s cannabis consumer won’t just smoke it; they’ll drink it, eat it, rub it on, take it as a pill, or wear it as a patch. They’ll take bubble baths in it.” This may at first sound like an exaggeration, but more and more companies have been working to come out with new solutions to using cannabis in the simplest ways. These new products have been working to shape the new industry, including new tech start-ups devoted to making the use of cannabis as easy as possible.

Continue reading
  0 Comments
0 Comments

Marijuana Stocks to Look Out For as Canada Legalizes Recreational Cannabis

Canada recently approved legislation that will effectively allow recreational cannabis to be consumed and distrusted throughout the nation. This new legislation represents the first time a developed nation has legalized the adult-use of cannabis nationally, which is quite a large milestone as far as the industry is concerned.

The Prime Minister of Canada and avid supporter of legal cannabis, Justin Trudeau, recently stated that the new recreational laws will go into effect as soon as October 17th. The bill known as C-45 or the Cannabis Act was voted on as of Tuesday night, June 19th, and passed through the Senate vote with a large majority. Because of this, many stocks in the industry managed to climb in price, especially those concerned with the cannabis market in Canada.

The marijuana stocks at the top of the industry such as Canopy Growth (NYSE:CGC) have managed to come up in value by as much as 6.4% with others like the Cronos Group (CRON) moving up by around 5.25%. Many ETFs in the space also saw a rise in price with this news such as the ETFMG Alternative Harvest (MJ) which rose by around 2.35%. This is fair to assume however, as the market currently operates a lot on speculation given how new the industry still is. One of the other large players in the ancillary industry associated with cannabis is Scotts Miracle-Gro (NYSE:SMG). Scotts is a company that provides many different products for those attempting to grow cannabis whether it be outdoors or with hydroponic methods. The stock has come to light as the marijuana industry has changed so rapidly in the past several years.

Many Canadian stocks have been working to try and cement ties with the U.S. industry, such as the company Tilray, which filed on Wednesday for an IPO to list on the NASDAQ. The company released a statement that said “we are pioneering the future of medical cannabis research, cultivation, processing and distribution globally, and we intend to become a leader in the adult-use cannabis market in Canada once legalized. Many stocks in the cannabis industry have been working to come on board with the prestigious stock exchanges in the U.S. such as the listing of the Cronos Group earlier in the year. The company Aurora Cannabis, one of the largest marijuana producers in Canada, stated that they will be seeking new investments in the U.S. by utilizing a subsidiary as opposed to listing as a whole on the exchanges.

The company Aurora released a statement that “Recent changes in U.S. federal positioning with respect to cannabis have positively impacted the perception of risk to invest in U.S. cannabis assets,” Toronto Stock Exchange-listed Aurora said in a statement. “Entering the U.S. market now, in compliance with regulatory requirements, represents a risk/reward balance that is attractive to a well-connected and funded operators.”

Continue reading
  0 Comments
0 Comments

Marijuana Stocks Newsletter – Happy Thursday – June 21, 2018

Good Morning & Happy Thursday! – 6/21/2018!

InCaseYouMissedIt: What Does Canada’s Legalization Mean For Pot Stocks?Unless you’ve been living under a rock, you know that the cannabis industry has been heating up for the last four years. A big move being made but our neighbors to the north could give investors one of the biggest calls to action with Canadian marijuana stocks taking center stage.Read The Full Article Here

Investing in the 2018 Cannabis MarketThe cannabis market throughout the past several years has managed to be extremely lucrative for those who have decided to invest. With new legal measures being put in place around the world and especially in North America, it seems like now is a better time than ever to look into the marijuana industry.Read The Full Article Here

What’s The Next Big Wave For MJ?With Canada’s recreational MJ industy recently being legalized, cannabis stocks are captivating the markets. And if you’ve been following along, you would have already seen that one particular MJ Stock could be making a new trend and we’ve got the details for you, here.Read The Full Report

This email is for ‘%%emailaddress%%’ You have received this email because you are subscribed to MarijuanaStocks.com | Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of MAPH Enterprises, LLC owner of MarijuanaStocks.com and Leafbuyer Technologies, Inc, we were hired for a period from 2/2/2018 – 5/2/2018 to publicly disseminate information about (LBUY) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for & were paid “77,000” shares of restricted common shares. We own zero shares of (LBUY), which we purchased in the open market. Once the (6) Six month restriction is complete on 8/2/2018 we plan to sell the “77,000” shares of (LBUY) that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and Beleave Inc., Midam has been paid $200,000 from the company and ZERO shares of Beleave Inc. for a duration of 6 weeks beginning June 18, 2018 and ending July 31, 2018. We may buy or sell additional shares of (BLEVF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Continue reading
  0 Comments
0 Comments

Aphria Inc. (APHQF) Malta-based subsidiary, ASG Pharma, receives first import license for cannabis

Aphria’s Malta-based subsidiary, ASG Pharma, receives first import license for cannabis issued by the Malta Medicines Authority

Aphria Inc. (“Aphria” or the “Company“) (TSX: APH and US OTC: APHQF) today announced that its Malta -based subsidiary ASG Pharma (“ASG“), a high-capacity EU GMP-certified lab, is the recipient of the first import license for medical cannabis issued by the Malta Medicines Authority (“MMA“). The license will allow ASG to import medical cannabis for analytical testing and research and is an important step that will enable ASG to become a cornerstone in testing, research and development of medical cannabis in Europe .

” Malta’s legislative and regulatory standards are extremely rigorous, and we are pleased and proud that the MMA has awarded this import license to ASG,” said Antonio Costanzo , Head of International Development at Aphria. “ASG adheres to the highest international standards and we look forward to upholding this high bar as a leading European hub for medical cannabis.”

ASG Pharma is currently undergoing a multi-million-euro upgrade of its processing and manufacturing capabilities that will result in its ability to process, extract package and label pharmaceutical-grade medical cannabis and cannabis derivative products.

“Our EU GMP-certified lab in Malta will not only be a leading European center for R&D and testing, but also will provide a gateway to medical cannabis markets across Europe ,” said Vic Neufeld , CEO of Aphria. “We continue to pursue the most attractive strategic opportunities for medical cannabis in Europe and around the world, and this initial license sets the stage for ASG’s long-term future as Aphria’s processing, manufacturing and distribution hub for the entire continent.”

Continue reading
  0 Comments
0 Comments

Investing in the 2018 Cannabis Market

The cannabis market throughout the past several years has managed to be extremely lucrative for those who have decided to invest. With new legal measures being put in place around the world and especially in North America, it seems like now is a better time than ever to look into the marijuana industry.

The weed market is still very much in its infant stages which means that there is a large amount of room to grow, as well as a large amount of information that comes only with time. Debra Borchardt, co-founder, and editor-in-chief of the Green Market Report states that one should first learn whether or not the company makes “any profits or have a realistic chance of making profits? Does it disclose all the critical information in an earnings press release? Who are the insiders and management team?” These are usually the first questions that one should ask before putting money into any stock let alone the cannabis market. Most companies in the industry are extremely transparent and have the majority of their financial information in easily accessible websites online. She continued to state that one should consider “the team, business model and revenue, and company history.” The common sentiment seems to be that someone should first look into the details of the company regarding financials, and who the team consists of. These should always be the most important factors in making a decision on whether to invest or not.

One of the newest things to look for in the growing cannabis market is the production capacities of a company. Since there are many different and large growers in the industry, one of the main things that continue to separate these companies is the amount of production that they are capable of. Many companies have been upping their output, especially in North America, given the new recreational legalization across Canada.

Borchardt states further that in regard to the Canadian market, “I think that the Canadian stocks are extremely overvalued and will correct at some point. The problem is that I can’t predict when that will happen.” Although many economists have echoed a similar opinion, it seems as though the first correction has potentially happened, given the state of the current market. Many have stated that there may be an issue with oversupply given the growing growth capacity with the anticipation of legalization, but this may be positive in the end. The overproduction could likely result in lowering prices of cannabis, which not only would bring more customers into the industry, but it would help one of the newest parts of the market; export.

Lastly, one of the main focuses of many investors looking to get into the industry has been through the ancillary markets that are associated with cannabis. These ancillary markets present a very solid way to make an introduction into the industry without a direct exposure to the market. The ancillary industries such as packaging, marketing and so on have managed to provide some of the best and most consistent returns in the industry as they are not as subject to volatility and market fluctuations as stocks that touch that physical cannabis plant.

Continue reading
  0 Comments
0 Comments

Emblem Corp. (EMMBF) to Launch Emblem Germany in Joint Venture with Acnos Pharma

Emblem to Launch Emblem Germany in Joint Venture with Acnos Pharma

Emblem Corp. (EMC.V) (EMC-WT.V) (EMMBF) (“Emblem” or the “Company”), is pleased to announce that its Board of Directors has approved the Company’s formation of a joint venture under the name “Emblem Germany” (the “JV”) with German pharmaceutical wholesaler Acnos Pharma GmbH (“Acnos”) for the purpose of exporting Emblem branded cannabis products from Canada and importing them into Germany.  Subject to completion of definitive agreements with respect to the JV, the JV will be 60% owned by Emblem and 40% owned by Acnos.

With a population of approximately 82 million and federal health insurance coverage for medical cannabis, Germany’s adoption of cannabis has created one of the largest legal medical cannabis markets in the world.

Subject to all applicable regulatory approvals and the entering into of definitive agreements setting out the terms of the JV, Emblem will supply the JV with cannabis oil for sale to German pharmacies, wholesalers and clinical labs for medical purposes.  Teams from both companies are actively working to prepare and finalize definitive agreements setting out the terms of the JV, with the objective to commence export sales to Germany in 2019.

“Forming Emblem Germany with Acnos supports our market development efforts to establish world-class distribution channels in the regions where cannabis use is federally legal,” said Nick Dean, President and CEO of Emblem.  Upon completion, Emblem’s new 30,000 square foot Good Manufacturing Practices (“GMP”)-certified extraction facility will provide increased oil production capacity and significantly increase its extract and derivative product output to meet the expected demands of the German market.

“We have been impressed with the approach and progress Emblem’s medical division has made in establishing cannabis as a pharmaceutical product,” said Dirk Simonis, CEO of Acnos. “Emblem’s medical product innovation strategy is aligned to ours. We believe that medical cannabis products in Germany should be prepared in metered dose-controlled formats that physicians will feel confidence prescribing. From our experience, the long view of the German medical market is focused on oil extracts vs combustible products.”

Continue reading
  0 Comments
0 Comments

Future Farm Technologies Inc. (FFRMF) Announces Shareholder Meeting Dates and Update Regarding NexTech Spin-Off

Future Farm Announces Shareholder Meeting Dates and Update Regarding NexTech Spin-Off

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce that the formal process for completing the distribution of 11,000,000 common shares of NexTech AR Solutions Corp. (“NexTech”) to the shareholders of Future Farm (the “Future Farm Shareholders”) on a pro-rata basis is now under way. The process began with the filing last week of a Notice of Meeting and Record Date for an Annual General and Special Meeting to take place on July 26, 2018.  That notice is available on the CSE.

The distribution of the NexTech common shares is to be completed pursuant to a court-approved Plan of Arrangement.  The next step in the process is the application for an Interim Order from the British Columbia Supreme Court. The application for the Interim Order was filed yesterday and is set for a court hearing on June 21. Upon receipt of the Interim Order the Company will proceed to mail to the Future Farm Shareholders a proxy circular disclosing detailed information on the business of NexTech.

If the Arrangement is completed, Future Farm Shareholders will receive a total of 11 million common shares of NexTech while maintaining their current ownership interest in Future Farm. NexTech will apply to list its shares on the CSE following completion of the Arrangement.

NexTech will focus on the advancement and development of its revenue generating portfolio of gaming and all-in-one apps known as the “All-In-One-App Portfolio” using its augmented reality technology. NexTech has also expanded its augmented reality technology products and is working with a number of clients for the provision A/R enhanced marketing services including through its Native AR Platform and AR learning model.

The securities referenced in this news release have not and will not be registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”) or any state securities laws and may not be offered or sold within the United States unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Continue reading
  0 Comments
0 Comments

Aphria Inc. (APHQF) Applauds Passage of Bill C-45, a Historic Milestone for Canada and the Cannabis Industry

Aphria Applauds Passage of Bill C-45, a Historic Milestone for Canada and the Cannabis IndustryAphria Inc. (“Aphria” or the “Company“) ( TSX: APH and US OTC: APHQF) today provided the following statement in response to the passage of Bill C-45, the Cannabis Act:

Vic Neufeld , CEO of Aphria, said, “This is a historic milestone for our industry and for our country that will reverberate around the world as Canada solidifies its progressive leadership on cannabis. We are pleased to now have a regulatory framework for adult-use cannabis in place that sets the groundwork for the continuing evolution of this rapidly expanding industry. We applaud the Government’s consistent and conscientious efforts to protect public health and safety, restrict access to youth and eliminate the black market.”

“Today also represents an important milestone for our business, for which all of us at Aphria have been eagerly awaiting,” said Neufeld. “Thanks to the dedication of our incredible team, and our focus on innovation, R&D and our unmatched ability to grow high-quality, clean and safe cannabis to scale, we are ready to hit the ground running. Backed by our annualized production capacity of 255,000 kg by early next year, we are well prepared to the meet the anticipated demand in the adult-use market while continuing to serve the ongoing needs of our medical cannabis patients. We look forward to continuing to work with the Government as a long-term partner to evolve the industry in Canada and further its global success story.”

“We would like to acknowledge the work of government, industry, partners and all of our employees in getting us to this stage. As a country, we are already leading the way in medical cannabis, and it is thanks to the collaboration and diligence of all involved that we now have the opportunity to break new ground and set the standard for a successful adult-use cannabis regime in Canada .”

We Have A Good Thing Growing

About Aphria

Continue reading
  0 Comments
0 Comments

What’s The Deal With Cannabis Oils?

Cannabis oil and other derivatives from the marijuana plant have been around for some time now, but with new methods of research and a growing legal market, it seems that cannabis oils are bigger than ever. The cannabis market has been growing in legality in North America and around the world over the course of the past several years, and the new legal state of the plant has meant that more companies than ever are looking into how they begin to produce large amounts of cannabis oils.

First off, cannabis oils are the extracted chemicals from the cannabis plant, which when unprocessed contain around 100 or so active ingredients which all combine to help give many of the medical benefits of smoking cannabis in its natural form. According to one report “The two main active substances in cannabis plants are cannabidiol, or CBD, and delta-9 tetrahydrocannabinol, or THC. Oil extracted from hemp plants can contain a lot of CBD, while oil from skunk plants will contain far more THC. THC produces the high that recreational cannabis users seek, while oils for medical use contain mostly CBD.”

One of the most prominent reasons to use cannabis oils and extracts is the fact that the dosing is much easier to control and monitor as opposed to dried cannabis. The amounts of THC and CBD in the plant are very easily controlled in this method, and thus this information can be given to the patient to help ensure that they are getting the most quality medicine with the correct information.

In terms of medicinal benefits, the two main components of cannabis, THC, and CBD both have their own varying properties. CBD can work as an anticonvulsant, which means that it can be used to help reduce the frequency of seizures. CBD also has no psychoactive properties, which means that it does not get the user high. This helps to make the case for CBD being a promising treatment for children who have epileptic seizures but want an alternative to the traditional harsh pharmaceuticals that are often prescribed.

The industry on cannabis extracts has also been working to merge this with that of the pharmaceutical market. Many big companies have been researching new ways to include cannabis oils in pharmaceuticals to help with a wide variety of conditions and ailments. In recent news, the Food and Drug Administration will be considering whether or not to approve the drug Epidiolex, which is a CBD-derived medicine that can help to fight seizures. Around the world, many governments have been working to attempt to find some sort of legalization or fair legislation that would allow these patients to get the help that they need. The European Medicines Agency is scheduled to state a ruling on whether or not the drug should be legalized within the European Union, but that is all that has been said up to this point.

Continue reading
  0 Comments
0 Comments

Hemp, Inc. (HEMP) Applauds Senate Agriculture Committee for Passing Farm Bill with Hemp Legalization

Hemp, Inc. Applauds Senate Agriculture Committee for Passing Farm Bill with Hemp Legalization

Hemp, Inc. (OTC PINK: HEMP), a global leader in the industrial hemp industry with the largest multipurpose industrial hemp processing facility in the western hemisphere, announced today the company applauds the Senate Agriculture Committee for passing last Wednesday the 2018 farm bill in a 20-1 vote. The farm bill includes hemp legalization that is backed by Senate Majority Leader Mitch McConnell.

According to McConnell, hemp farming in Kentucky can help replace some of the revenue from falling tobacco demand, reported CNBC.

“I know there are farming communities all over the country who are interested in this,” said McConnell, according to CNBC. “Mine are particularly interested in it, and the reason for that is — as all of you know — our No. 1 cash crop used to be something that’s really not good for you: tobacco. And that has declined significantly, as it should, given the public health concerns.”

Officially known as the Agriculture Improvement Act of 2018, the draft farm bill contains more than 1,000 pages and covers everything from farm subsidies and food stamps to trade and rural development policy. Farmer assistance includes commodity payment programs, as well as subsidized crop insurance.

Hemp, Inc. announced its support in April for Senate Majority Leader Mitch McConnell’s introduction of a bill to remove industrial hemp from the federal government’s schedule of controlled substances.

Continue reading
  0 Comments
0 Comments

Marijuana Stocks Newsletter – June 20, 2018 – Happy Wednesday!

Good Morning & Happy Wednesday! – 6/20/2018!

SPECIAL REPORT: Canada’s Legalization Means Big Things for Pot StocksUnless you’ve been living under a rock, you know that the cannabis industry has been heating up for the last four years. A big move being made but our neighbors to the north could give investors one of the biggest calls to action with Canadian marijuana stocks taking center stage.Read The Full Article Here

How the Marijuana Market is Becoming InternationalCannabis legalization has been present in the U.S. and abroad for some time now, but lawmakers and companies are working to see how the market in North America could potentially work with the international industry of cannabis.Read The Full Article Here

What’s The Next Big Wave For MJ?With Canada’s recreational MJ industy recently being legalized, cannabis stocks are captivating the markets. And if you’ve been following along, you would have already seen that one particular MJ Stock could be making a new trend and we’ve got the details for you, here.Read The Full Report

This email is for ‘%%emailaddress%%’ You have received this email because you are subscribed to MarijuanaStocks.com | Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of MAPH Enterprises, LLC owner of MarijuanaStocks.com and Leafbuyer Technologies, Inc, we were hired for a period from 2/2/2018 – 5/2/2018 to publicly disseminate information about (LBUY) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for & were paid “77,000” shares of restricted common shares. We own zero shares of (LBUY), which we purchased in the open market. Once the (6) Six month restriction is complete on 8/2/2018 we plan to sell the “77,000” shares of (LBUY) that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Pursuant to an agreement between an affiliate of MAPH Enterprises, LLC, Midam Ventures LLC and Beleave Inc., Midam has been paid $200,000 from the company and ZERO shares of Beleave Inc. for a duration of 6 weeks beginning June 18, 2018 and ending July 31, 2018. We may buy or sell additional shares of (BLEVF) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. PLEASE READ OUR FULL PRIVACY POLICY & TERMS OF USE & DISCLAIMER

Continue reading
  0 Comments
0 Comments

How the Marijuana Market is Becoming International

Cannabis legalization has been present in the U.S. and abroad for some time now, but lawmakers and companies are working to see how the market in North America could potentially work with the international industry of cannabis. One of the biggest pieces of news to influence this has been Canada’s decision to legalize recreational and medicinal cannabis on a nationwide level. The country has been one of the main contributors to the idea of taking the market to the International level, but there are still some things that need to happen prior to that. Many companies within Canada, however, have already started to create these ties abroad, and here are just a few.

One of the most promising parts of the global cannabis industry has been the advent of the possibility that Africa could begin exporting cannabis across the continent. Africa as a whole has already stated that they grow somewhere around nine million kg of weed per year, but this growth has largely been not accounted for nor taken advantage of. Some nations such as Ghana, allow the use of cannabis on a non-legal level, but the possession of the plant is still illegal. Only two African nations allow the use of cannabis legally and those are Zimbabwe and Lesotho.

Lesotho has been on the radar of the market for some time now, as the conditions in the nation are quite well suited to grow cannabis. The country receives sunshine for around three hundred days out of the year which coupled with a high amount of humidity and warmth, makes it the perfect place to grow cannabis.

Aphria (TSX: APH) has been working to cement ties with Africa since a few months back when they began reaching out to the legal market in Lesotho. The company entered a joint venture with the company Verve Dynamics, with cost around $3 million to do. The two companies will help to bring the high-grade, low-cost cannabis from Verve Dynamics that is grown in Africa, to various markets around Europe and North America. The joint venture will effectively be known as CannInvest Africa and is poised to create a large amount of interest throughout the whole of the market.

Another company that has been interested in growth in Africa has been the large Canadian marijuana grower Canopy Growth Corporation (TSX:WEED), (NYSE:CGC). The company recently acquired the African company Daddy Cann Lesotho, which currently is trading under the name “Highlands”. The acquisition results in Canopy issuing around $30 million in shares, but this deal could help to give Canopy access to a population of over 55 million people, which could make it quite worth it in the future.

Continue reading
  0 Comments
0 Comments

 Tetra Bio-Pharma Inc. (TBPMF) Adds a New Leader for its Commercial Operations

Tetra Bio-Pharma Adds a New Leader for its Commercial Operations

 Tetra Bio-Pharma Inc., a leader in cannabinoid-based drug discovery and development (TSX VENTURE:TBP) (TBPMF), is pleased to announce that Mr. Richard Giguere has been hired as Executive Vice-President, Commercial Operations. He will be responsible for the commercial sales and operations of Tetra Natural Health and Tetra Veterinary Health.

Richard has more than 20 years’ experience in sales and marketing in the pharmaceutical industry from coast to coast. During his career, he has held various business development, management and negotiation positions and launched several new products on the Canadian market. He has worked for various pharmaceutical companies in sectors such as generics, branded products and medical devices. He has also worked with OTC, natural products and original medications. Richard is recognized for his deep ethical sense, respect of others and talent for developing long-term business relationships through flexibility and efficiency. In the past 10 years, he was also a board member at the companies for which he worked.

“We’re very proud to add Richard Giguere to our senior management team. His vast experience in the sales and marketing of OTC, natural health products and original medications in the pharmaceutical industry across Canada will help drive the execution of our corporate strategy for our Tetra Natural Health and Tetra Veterinary Health divisions,” says Guy Chamberland, Interim Chief Executive Officer of Tetra Bio-Pharma.

Richard Giguere’s arrival is perfectly aligned with Tetra Bio-Pharma’s decision to restructure its corporation by commercial markets. While Tetra Bio-Pharma will be dedicated to pharmaceutical development and commercialization of cannabinoid-based prescription drugs and treatments, Tetra Natural Health will develop and sell cannabinoid-based OTC (self-care) products to leverage the post-legalization market and Tetra Veterinary Health will focus on commercialization of cannabinoid-based products for the pet product market.

“I am honored to be able to play an active role in growing both the Tetra Natural Health and Tetra Veterinary Health divisions,” says Richard Giguere, EVP, Commercial Operations. “Tetra has a sound business model, and there are significant opportunities for us to grow our two commercial divisions. I am committed to making the best business and commercial decisions to accelerate the development of these huge potential markets for our cannabinoid-based products.”

Continue reading
  0 Comments
0 Comments

iMD Companies, Inc. (ICBU) Gives Corporate Update to Shareholders

iMD Companies, Inc., Gives Corporate Update to ShareholdersiMD Companies, Inc. (OTC PINK: ICBU) Board of Directors announced today that the company is completing its financials and expects to upload them to OTC Markets by next week. The company has submitted its application and payment to OTC Markets and expects the application to be approved this week. The company recently completed two acquisitions, SG Minerals Mining Company and LCG Plastech, a PVC pipe manufacturing Company. Both companies are wholly owned subsidiaries of iMD. The company had to wait until the audited financials were completed by both companies in order to complete the companies financials and disclosures. The financials have now been assembled and iMD expects to file with OTC Markets to become current in the upcoming week. iMD is pleased that the financials have been completed and both companies are headed in the right direction with increasing revenues and contracts. The company is also currently working on acquiring Gold mining claims and mines to add revenue and assets to the companies consolidated income statements and will update the shareholders as soon as completed.

About iMD Companies, Inc. www.imdcompaniesinc.com

iMD Companies, Inc., (ICBU) is a Florida corporation, engaged in the manufacturing, extraction and distribution in the mining industries and asset accumulation of revenue producing companies. The company is positioned to be a holding company for acquisitions in the mining industries. The company and the principals of the management team have extensive backgrounds in finance, manufacturing, marketing and distribution. ICBU’s goal is to create and increase shareholder value by tactically growing our business while strategically seeking to acquire new business and create other business alliances, which generate increased revenues and earnings.

Safe Harbor Statement:

Certain statements made in this press release constitute forward-looking statements that are based on management’s expectations, estimates, projections and assumptions. Words such as “expects,” “anticipates,” “estimates” and variations of these words and similar expressions are intended to identify forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, as amended. These statements are not guarantees of future performance and involve certain risks and uncertainties, which are difficult to predict. Therefore, actual future results and trends may differ materially from what is forecast in forward-looking statements due to a variety of factors. All forward-looking statements speak only as of the date of this press release and the company does not undertake any obligation to update or publicly release any revisions to forward-looking statements.

-222-2863

Continue reading
  0 Comments
0 Comments

Choom™ (CHOO.CN) (CHOOF) Secures 10 Additional Cannabis Retail Opportunities

Choom Secures 10 Additional Cannabis Retail Opportunities in Alberta and British Columbia

Choom (CHOO.CN) (CHOOF) (the “Company” or “Choom”) an emerging, fully-integrated cannabis company, is pleased to announce that it has advanced the build-out of its cannabis retail store network in Alberta and British Columbia .

Choom has secured the rights to an additional 7 retail locations in Alberta . Choom has 25 leases in highly strategic and secure locations in Alberta with 24 applications submitted. Choom has also secured 3 additional B.C. retail leases, combined with the existing 7, for a total of 10 retail opportunities in B.C. In all cases, the retail opportunities are subject to all necessary governmental and municipal approvals being granted. This number is expected to grow over the coming months as the Company is currently negotiating additional leases with the intention of submitting applications for retail licenses. The following link will bring you to our retail opportunity map: https://investors.choom.ca/wp-content/uploads/2017/11/ChoomRetailMap.pdf

“This is a significant step towards establishing Choom’s strategy to be a leading private cannabis retailer in Canada ,” states Choom’s President and CEO, Chris Bogart . “Market share and customer acquisition in the upcoming recreational landscape will be very difficult to come by, these applications are key to Choom’s retail strategy. Choom’s brand was created exclusively for the recreational market, core to our values is cultivating a great experience for the consumer and part of this strategy is retail distribution. We are committed to pursuing retail licensing opportunities across the country and remain focused on cultivating ‘Good Time with Good Friends’.”

SAY HELLO TO CHOOMTMChoom was created for and inspired by the Choom Gang; a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, “Choom”. Now, after four decades, Choom is bringing the spirit of Hawaii to Canada . Choom is focused on delivering an elevated customer experience through our curated retail environments, high-grade handcrafted Cannabis supply, and a diversity of brands for the Canadian recreational consumer.

We’re planting our flag in the rapidly growing legal cannabis industry in Canada with our own brand of high-grade handcrafted herb. For additional information please visit us at: www.choom.ca

Continue reading
  0 Comments
0 Comments

Comparing Some of the Top Players in the Marijuana Stock Market

The marijuana market has been extremely lucrative for some time now, but with new legislation across North America and abroad, many companies have come to the forefront of the industry showing new ways to grow and export cannabis that has never been done before.

The companies CannTrust Holdings (NASDAQOTH:CNTFF) and Organigram Holdings (NASDAQOTH:OGRMF), have both been some of the largest players in the cannabis growing space. The two companies share a large amount of similarities including being from Canada and sharing a similar trajectory, but both companies still present a very interesting case to investors.

The two companies are in no way the same, but investors have compared them greatly over the past year or so. CannTrust has been at the forefront of the weed revolution in Canada for some time now, and recently posted earnings of around $11.4 million Canadian dollars in their first quarter. This makes this quarter the third consecutive quarter of taking in profits.

One of the biggest factors of growth for CannTrust has been that they take in 60% of their sales from cannabis extracts, which has been a market that has frown very quickly. The sales are also growing very rapidly for CannTrust, which means that the next quarter’s revenue could potentially continue to show a large amount of profit.

The company has yet to move into the international market as many other Canadian giants have done, so currently, all of their profits have come from the domestic market in Canada. The company recently teamed up with another cannabis company known as Apotex, which is the largest pharmaceutical company of generic drugs in Canada, and listed as the seventh largest throughout the world. CannTrust has also been working to grow their business domestically due to the impending recreationally legal market that has been growing there for some time now.

Continue reading
  0 Comments
0 Comments

Marijuana Stocks Newsletter Tuesday, 6/19/2018

READ THIS: Canada’s Legalization Means Big Things for Pot Stocks

Unless you’ve been living under a rock, you know that the cannabis industry has been heating up for the last four years. A big move being made but our neighbors to the north could give investors one of the biggest calls to action with Canadian marijuana stocks taking center stage.

Read The Full Article HereDon’t Mess with Texas: Texan Republican Party announced backing of industrial hemp and they’re not backing down

45 years ago, those in possession of marijuana in Texas faced a charge of life in prison; on Saturday, however, Texan Republican Delegates voted to endorse the decriminalization of industrial hemp.

Read The Full Article HereWhat’s The Next Big Wave For MJ?

With Canada’s recreational MJ industry recently being legalized, cannabis stocks are captivating the markets. And if you’ve been following along, you would have already seen that one particular MJ Stock could be making a new trend and we’ve got the details for you, here.

Read The Full Report

Disclaimer:

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of MAPH Enterprises, LLC owner of MarijuanaStocks.com and Leafbuyer Technologies, Inc, we were hired for a period from 2/2/2018 – 5/2/2018 to publicly disseminate information about (LBUY) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for & were paid “77,000” shares of restricted common shares. We own zero shares of (LBUY), which we purchased in the open market. Once the (6) Six month restriction is complete on 8/2/2018 we plan to sell the “77,000” shares of (LBUY) that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Continue reading
  0 Comments
0 Comments

Don’t Mess with Texas: Texan Republican Party announced backing of industrial hemp and they’re not backing down

45 years ago, those in possession of marijuana in Texas faced a charge of life in prison; on Saturday, however, Texan Republican Delegates voted to endorse the decriminalization of industrial hemp.

According to Civilized.com, those convicted of marijuana possession in 1923 Texas paid a steeper price. It wasn’t until 50 years later that the state changed those laws. Today, Texas’ state law says that possession of up to two ounces is a criminal offense punishable by incarceration of up to six months and a $2,000 fine. In a state where the drug was once banned, this recent vote from Delegates at the Republican Party of Texas Convention ahead of the 2019 legislative session could change all that. In addition to formulating platforms upon which marijuana decriminalization, industrial hemp, and medical marijuana would be endorsed, Republicans also agreed to rally behind change for the way the federal government classifies the drug.

Currently, marijuana is seen as a Schedule 1 drug, on the same level as heroin and LSD. Despite the federal viewpoint on the classification of this controversial drug, more and more states continue to legalize the use of the plant in one way or another. In 2015, Senate Bill 339, also known as the Texas Compassionate-Use Act, affirmed that low-THC could be distributed to patients who qualify for medical marijuana as treatment. Saturday’s vote further delved into the party’s positions on medical marijuana which patients currently have limited access to.

Last year, the vote to increase the access of medical marijuana to patients received massive support. The legislative session, however, ran out of time before floor votes could be conducted. With the next legislative session beginning in January, cannabis backers hope that the increased Republican support will give the issue the traction it needs to push it over the edge. One of the new positions taken by the party also recognizes the plant’s value as an agricultural commodity. In it, they implore Texas Legislature to pass legislation on the drug that would permit the sale, cultivation, and manufacturing of industrial marijuana and marijuana-related products. Additionally, they encourage that the law is changed so that marijuana possession is no longer classified as a criminal offense, but a civil one. This means that legal adults, aged 21 years and older, found with up to one ounce of marijuana on their person would be punished by a $100, but go without having to serve a jail sentence.

As it would seem, marijuana has some friends in high places, and it only appears to be rallying more Republican supporters as opinions shift. U.S. Senate Majority Leader Mitch McConnell recently pushed for the 2018 Farm Bill and President Trump announced this month that he would back bipartisan efforts to lift the federal ban on the drug so that states could regulate their own cannabis laws. With Texas currently arresting tens of thousands of its citizens for marijuana-related crimes each year, this change in opinion is a major breakthrough for cannabis advocates. However, for as many allies as the drug has, there are still those who oppose it. An avid adversary to marijuana legalization is one of Texas’ own, Republican Rep. Pete Sessions. Despite his party’s recent support of the drug, Sessions has used his position as chairman of the House Rules Committee to block marijuana votes. These include a vote that, if passed, would have given veterans access to marijuana as a treatment for symptoms of PTSD, pain management, and other conditions. Sessions’ actions to impede marijuana legalization can only hold on for so long as more conservatives come out in support of the drug. Considering the party’s ongoing and turbulent history of opposition, these new positions by Republicans comes as a surprise to many but also signifies something of greater importance. Has the fact that the drug has gone mainstream shifted political views enough to bring the country that much closer to full-blown legalization?

Continue reading
  0 Comments
0 Comments

MJ Stocks Newsletter Monday, 6/18/2018

Canada’s Legalization Means Big Things for Pot Stocks

Unless you’ve been living under a rock, you know that the cannabis industry has been heating up for the last four years. A big move being made but our neighbors to the north could give investors one of the biggest calls to action with Canadian marijuana stocks taking center stage.

Read The Full Article HereChoom (CHOOF) Announces Closing of $10.1 million Private Placement

Choom (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom”), an emerging fully-integrated cannabis company, is pleased to announce it has closed its previously announced non-brokered private placement ( June 13, 2018 ). The Company issued 14,225,352 shares for total gross proceeds of $10.1 million. Aurora Cannabis is the cornerstone investor in the placement with a lead order of $7 million. All securities issued are subject to a four-month hold period.

Read The Full Article HereWhat’s The Next Big Wave For MJ?

With Canada’s recreational MJ industry recently being legalized, cannabis stocks are captivating the markets. And if you’ve been following along, you would have already seen that one particular MJ Stock could be making a new trend and we’ve got the details for you, here.

Read The Full Report

Disclaimer:

Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of MAPH Enterprises, LLC owner of MarijuanaStocks.com and Leafbuyer Technologies, Inc, we were hired for a period from 2/2/2018 – 5/2/2018 to publicly disseminate information about (LBUY) including on the Website and other media including Facebook and Twitter. We are being paid $100,000 (CASH) for & were paid “77,000” shares of restricted common shares. We own zero shares of (LBUY), which we purchased in the open market. Once the (6) Six month restriction is complete on 8/2/2018 we plan to sell the “77,000” shares of (LBUY) that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of (LBUY) in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information.

Continue reading
  0 Comments
0 Comments

Canada’s Legalization Means Big Things for Pot Stocks

Unless you’ve been living under a rock, you know that the cannabis industry has been heating up for the last four years. A big move being made but our neighbors to the north could give investors one of the biggest calls to action with Canadian marijuana stocks taking center stage.

Canada is likely to legalize recreational marijuana this summer, which could be a big catalyst for cannabis stocks and right now investors interested in pot stocks should pay close attention to the industry, heading into this big move. But what’s the name of the game for 2018?

It would seem that acquisitions and investment deals are fueling the fire so for investors looking for opportunity, the very key could be finding companies that are building a brand & real niche marketplace for themselves.

Case and point, just look at what has happened within the last 8 months.  Back in October, it was widely publicized that one of the largest beer, wine, and spirits companies in the world, Constellation Brands (STZ) was going to acquire a minority (9.9%) stake in Canopy Growth (CGC).

Had you invested in Canopy back when it was just beginning to put the wheels in motion, you would have seen a stock trading around $1.30. Today that same “small cannabis company” trades at a price of over $30 per share! So what could be the next “Canopy” opportunity?

Continue reading
  0 Comments
0 Comments

Aurora Cannabis Inc. (ACBFF) Closes Strategic Investment in Choom Holdings

Aurora Cannabis Closes Strategic Investment in Choom Holdings

Aurora Cannabis Inc. (“Aurora” or the “Company”) (ACB.TO) (ACBFF) ( Frankfurt : 21P; WKN: A1C4WM) announced today that it has closed its previously announced $7 million investment in Choom Holdings Inc. (“Choom”), whereby Aurora received 9,859,155 common shares from Choom’s treasury, priced at $0.71 per share, representing a 6% ownership interest. In total, Choom issued 14,225,352 shares for total gross proceeds of $10.1 million . All securities issued are subject to a four month hold period.

Since the announcement of the private placement, Choom closed its previously announced acquisition of Specialty Medijuana Products Inc. (“SMP”). SMP recently completed construction of its 10,000 square foot Sooke, British Columbia facility and expects to receive its cultivation license from Health Canada in the third quarter of 2018. In addition, SMP intends to expand production capacity by and additional 19,600 square feet at the Sooke facility, bringing the total capacity to 29,600 square feet. SMP has also submitted plans to construct two separate hybrid greenhouse facilities on the grounds of the Sooke Facility, which when completed would bring total production capacity to over 700,000 square feet.

Management Commentary

“This strategic investment positions Aurora to participate in the emerging craft cultivation market, as well as in an exciting Western Canada retail strategy with a seasoned team of executives,” said Terry Booth , CEO of Aurora. “Choom’s product cultivation strategy puts the cultivar first, developing a high-grade offering with unique flavour profiles, which are anticipated to resonate strongly with the adult-use consumer market, once legalized. We’re pleased to close our investment in Choom, and look forward to building a strong, long-term relationship with the team.”

Chris Bogart , President & CEO for Choom, added, “The financing provides us with the funds to accelerate the execution of our unique retail strategy moving forward. We are now well positioned to expand our production and retail footprint, and pursue further opportunities across Canada .”

Continue reading
  0 Comments
0 Comments

How the Cannabis Industry is Becoming More Diversified

The cannabis industry has managed to draw a large amount of attention over the past few years or so, but a little-known fact throughout the market comes from the lacking representation of minorities in the industry.

Shanita Penny, the president of the board of directors for the Minority Cannabis Business Association, took a complaint following a racially motivated naming of a cannabis strain. The organization run by Penny, ha the goal of diversifying the cannabis industry to help give a more accurate representation of those who are involved in the market. She stated that the marijuana industry around the country is still overwhelmingly run by a white majority. One study states that around less than one percent of owners of marijuana dispensaries in the U.S. are owned by black people. Another survey states that “less than 19 percent of the nation’s marijuana businesses have minority investors. With the federal prohibition of marijuana still in place, data remains woefully inadequate on the exact makeup of the nation’s marijuana business owners. But if the last survey is accurate, that means a whopping 81 percent of the nation’s marijuana businesses are white-owned.”

This number is something that undoubtedly needs to be changed as the U.S. is a diverse country full of people from all types of backgrounds. Congresswoman Barbara Lee, a Democrat from California states that she will be introducing something known as the RESPECT Resolution. This is the first piece of legislation introduced into congress to help solve the racial disparity in the cannabis industry. She stated that her goal is to try to encourage states to bring those who are underrepresented, into the industry in larger numbers. This way, the industry as a whole can grow in greater numbers.

The resolution means that states and localities will effectively be able to have the ultimate decision on what happens, but they can choose to vote on it individually. She has stated that she is confident that it will send a large signal to lawmakers who are wishing to make a change in the industry.

The legislation would also effectively “urge states to completely expunge the records of people incarcerated for non-violent marijuana offenses. It also asks them to drop the fees to even apply for a marijuana license (like New York’s $10,000 non-refundable fee), to allow people formerly incarcerated for marijuana to access this new marijuana regulatory system.” Some states like Illinois, an individual with a felony record cannot even have a shot at getting a marijuana card, which given the racial inequality in terms of jailed demographics, this makes it seem that much more unjust.

Continue reading
  0 Comments
0 Comments

Big Deals Are Emerging In The Canadian Marijuana Space

The Canadian cannabis market has been explosive for many reasons over the past several years, but most notably the state of legal cannabis has meant that investors have continued to flock into the market. This influx of capital has led to a large amount of market growth in a short period of time, and has also led to a high amount of mergers throughout the industry. Canada recently voted to allow recreational cannabis for anyone over the age of 21, and this new bill will go into effect some time in the coming months.

The legal cannabis market in Canada will effectively be able to add as much as $5 billion in revenue to the market and that is the lowest estimate. This also means a lot more money going back into the pockets of producers, who can then use these profits to continue growing the industry even further.

One of the main issues in the industry has been the attempt to get legitimate capital from banks or other financial institutions. According to one report “Canadian banks have almost universally stayed away from the weed industry in Canada for fear of criminal and/or financial penalties associated with offering basic banking services to pot stocks.” This type of taboo surrounding cannabis is nothing new and is simply a product of the past hundred or so years of cannabis in the media.

The only option for these companies to raise capital has been through the listing of Canadian stocks and bought-deal offerings. This means according to one report that it is “a means to raise capital by selling common stock, convertible debentures, stock options, and/or warrants to an investor or group of investors prior to the release of a prospectus. Bought-deal offerings have been widely successful in raising capital that pot stocks have used to grow their production capacity. In fact, this past week, one giant marijuana stock announced what’s now the largest bought-deal offering in the history of the Canadian weed industry.”

The company Aphria has continued to be at the top of the cannabis market and recently became the subject of the largest bought deal financing offer to happen in several years. The bought-deal agreement will mean that around 19 million shares of common stock will be “ sold for $11.85 Canadian dollars ($9.13 U.S. dollars) per share. An underwriters’ option exists as well that could allow for an additional 2.84 million shares to be purchased. Without the underwriters’ option, this is a CA$225 million offering ($173.3 million). Including the underwriters’ option, assuming it’s exercised, this is a CA$258.8 million offering ($199.4 million).” This deal is quite massive considering the recent bought-deal financing of around CA$200 million from Aurora and Canopy Growth that went on a few months ago.

Continue reading
  0 Comments
0 Comments

Choom™ (CHOOF) Announces Closing of $10.1 million Private Placement

Choom Announces Closing of $10.1 million Private Placement

Choom (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom”), an emerging fully-integrated cannabis company, is pleased to announce it has closed its previously announced non-brokered private placement ( June 13, 2018 ). The Company issued 14,225,352 shares for total gross proceeds of $10.1 million . Aurora Cannabis is the cornerstone investor in the placement with a lead order of $7 million . All securities issued are subject to a four month hold period.

“The financing provides us with the funds to accelerate the execution of our unique retail strategy moving forward.” States Chris Bogart , CEO and President of Choom. “We are now well positioned to expand our production and retail footprint, as well as, pursue further opportunities across Canada .”

None of the securities issued in connection with the placement will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there by any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

SAY HELLO TO CHOOMTM

The Choom brand is inspired by Hawaii’s “Choom Gang”- a group of buddies in Honolulu during the 1970’s who loved to smoke weed—or as the locals called it, choom. Evoking the spirit of the original Choom Gang , our brand is synonymous with cultivating good times with good friends. We are focused on delivering an elevated customer experience through our curated retail environments, high-grade handcrafted cannabis supply, and a diversity of brands for the Canadian recreational consumer.

Continue reading
  0 Comments
0 Comments

Grow Condos, Inc.,(GRWC) Fully Retires Convertible Debt

Grow Condos, Inc. Fully Retires Convertible Debt

Grow Condos, Inc.,(GRWC) announces that all notes issued pursuant to the Company’s 2016 debt offerings have been retired and the Company has no further obligations under the notes of those offerings. “We’re excited to have this convertible debt fully retired as we continue to strengthen Grow Condos’ balance sheet and drive shareholder value,” Chief Executive Officer Wayne Zallen stated. “Our stock had been under enormous pressure due to the large amount of debt converted into shares and introduced into the market, and the dilution of the stock has been a concern to us and all of our shareholders. To see the conclusion is a relief to all of us. We are aware that going forward we will need to generate sufficient revenues to become self-financing. Should we need capital to fund future operations, we will strive to be more judicious in the terms of such financing.  We are confident that this approach will result in better shareholder value.”

About Grow Condos, Inc.: Grow Condos is a publicly traded company listed under the symbol GRWC.  We own and manage a 15,000-square foot condo style warehouse in Eagle Point, Oregon, Smoke On The Water, a 420 friendly campground located in Lake Selmac, Oregon, and a property in Eugene, Oregon.

Safe Harbor: This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of Grow Condos, Inc, its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words “may,” “would,” “will,” “expect,” “estimate,” “can,” “believe,” “potential” and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond Grow Condos, Inc.’s ability to control, and that actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in Grow Condos, Inc. filings with the OTC Markets, Securities and Exchange Commission and/or the company’s website.

CONTACT:Grow Condos, Inc.Corporate: www.growcondos.comTwitter: https://twitter.com/GrowCondosIncInvestor Relations: 

The post Grow Condos, Inc.,(GRWC) Fully Retires Convertible Debt appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Original link
  0 Comments
0 Comments

Marijuana Stocks Newsletter – Happy Friday June 15, 2018

Good Morning & Happy Friday! – 6/15/2018!

Choom (CHOOF) Announces Closing of Specialty Medijuana ProductsChoom (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom“), an emerging fully-integrated cannabis company, is pleased to announce that today it is closing its acquisition (the “Transaction“) of Specialty Medijuana Products Inc. (“SMP“) pursuant to an amended and restated amalgamation agreement among Choom, Arbutus Brands Inc. and International Tungsten Inc. The Company announced the definitive agreement to effect the Transaction in a news release on March 19, 2018.Read The Full Article Here

What’s The Next Big Wave For MJ?With Canada’s recreational MJ industy recently being legalized, cannabis stocks are captivating the markets. And if you’ve been following along, you would have already seen that one particular MJ Stock could be making a new trend and we’ve got the details for you, here.Read The Full Report

The Marijuana Market in Uruguay Runs Into Supply Problem

The legal cannabis market around the world has seen a large boom over the course of the past five years. One of the earlier international markets to come into the space was Uruguay, legalizing the use of cannabis as of five years ago in 2013. The law in Uruguay states that consumers can buy up to 1.5 ounces of the substances or 40 grams, but purchasing cannabis domestically has become a challenge in itself.Read The Full Article Here

Continue reading
  0 Comments
0 Comments

The Marijuana Industry Continues To Grow At a Rapid Pace

The cannabis market has been growing at quite a substantial rate over the course of the past five or so years. With a large amount of support from the public, it seems as though the marijuana industry is just now getting started.

A new report shows that the U.S. marijuana industry could potentially reach as much as $22 billion in the next four or so years by 2022. This number is quite large considering where cannabis currently is at around $6 billion. The tripling of value in the industry is something that has not before been seen and seems to be the main drawing factor for investors to continue coming into the space. Not a lot of industry can produce this kind of growth, but marijuana continues to highlight the perception of the drug and its usefulness as the main reason for this massive growth.

The marijuana industry seems like it has no place to go but up according to many studies done recently. Currently, in the U.S., there are as many as 30 states with some sort of legal measures put in place for use of cannabis by the public. Nine of these states including the District of Columbia allow the use of recreational cannabis for those who are over twenty-one years old. The newness of this industry can only be shown in the fact that many of these states have only recently put this new legislation in place such as Arkansas, Florida, North Dakota and others. With the large and growing California market only going into effect earlier this year, it seems as though this is just the beginning of the massive growing market in the U.S. and beyond. Many states have also been working to cement new legislation for the industry to allow the use of recreational cannabis and not just medicinal use, which could help to boost the revenue of the greater market overall.

One figure shows that “Colorado’s recreational marijuana market opened in 2014. Total marijuana sales that year (including medical and recreational marijuana) were nearly $684 million. Based on year-to-date revenue figures in Colorado, the state’s total marijuana sales in 2018 will probably be around $1.6 billion. That’s 134% growth in five years.” When looking at numbers like this, it is easy to see how the growth of the industry could continue to meet these high expectations in the coming years.

One stock that has continued to shock investors without even having a direct tie to the physical cannabis plant is the company Scotts-Miracle Gro (NYSE:SMG). The company has presented a new way to invest in the cannabis market and has helped to build the idea of ancillary industries that so many investors have been flocking to. Scotts traditionally is a company that offers solutions for growing plants, but as they realized the massive nature of the cannabis market, the company has been specifically producing new products to help meet the growing demand of the cannabis industry, and has marketed these products as such. Scott also recently acquired the company known as Sunlight Supply, which works by distributing hydroponic products to the U.S.

Continue reading
  0 Comments
0 Comments

Why States Should be In Charge of Their Marijuana Industries

The marijuana industry across the U.S. has been in quite a topsy-turvy state for some time now as the ongoing battle between state and federal regulators has made the market difficult to dissect from a legal perspective. A new bill coming to the federal government may help solve this issue of power dynamic between what the states deserve and what the national government would like to see.

There are currently nine states in the U.S. that allow the use of adult-use recreational cannabis. These states have worked to grow quite sizable markets on growing, distribution and the individual retailers who sell the plants to the public. This means that anyone over the age of 21 can purchase marijuana in its varying forms throughout these states. This has been a large paradigm shift to the way that marijuana has been dealt with in the U.S. up until the past five to ten years. The recreational markets in these states are in a direct defiance to the law of the federal government. The U.S. government states that cannabis is currently a Schedule I narcotic. This means that from their perspective, cannabis has no potential for use in a medicinal setting as well as having a high possibility of addition. Both of these statements have been refuted many times by scientific journals and doctors alike around the world. The scheduling of the substance mostly refers to the paranoia surrounding the substance after a series of propaganda was released back in the early 20th century. It very obviously appears that the legislation needs to change, and this is precisely why the federal government has been hesitant to interfere fully with these legal markets.

A new bill has come out and could likely be signed into law in the coming weeks known as the Marijuana STATES act. The bill would effectively amend the substances scheduling on the Controlled Substances Act, and allow states the right to control their own internal marijuana industries. According to one report “ legal weed has flourished only because federal law hasn’t been enforced. The medical-marijuana business, still small, been protected for years by a rider to appropriations bills that bars federal money from funding their prosecution.”

The Obama administration was the first to offer the states some sort of protection under what is known as the “Cole Memo.” The Cole Memo meant that federal prosecutors had to take cannabis off of their priority in terms of prosecution, and thus states could act accordingly. The main opponent who worked to rescind this bill in the early parts of this year has been Attorney General Jeff Sessions. Sessions has been the primary reason that no new laws have been put into place.

The new STATES Act has been pushed forward by several individuals in government such as Senator Cory Gardner and Elizabeth Warren. The new bill aims at changing the current state of cannabis, and hopes to change the legislation that for too long, has not reflected at all the view of the public on cannabis. The market on cannabis in the U.S. and its legal status is still very new, which means that these small steps are all working in conjunction to help produce a better way for the country to deal with the use of legal cannabis nationwide. The hopes are high that these steps will all take the industry in the right direction, allowing the market to function as it should, and giving better access to cannabis for those who wish to use it and those who need it.

Continue reading
  0 Comments
0 Comments

Choom™ (CHOOF) Announces Closing of Specialty Medijuana Products

Choom Announces Closing of Specialty Medijuana Products

Choom (CSE: CHOO; OTCQB: CHOOF) (the “Company” or “Choom“), an emerging fully-integrated cannabis company, is pleased to announce that today it is closing its acquisition (the “Transaction“) of Specialty Medijuana Products Inc. (“SMP“) pursuant to an amended and restated amalgamation agreement among Choom, Arbutus Brands Inc. and International Tungsten Inc. The Company announced the definitive agreement to effect the Transaction in a news release on March 19, 2018 .

“We are excited to add SMP to the Choom group of companies under our Arbutus Brands subsidiary,” states Chris Bogart , President and CEO for Choom.  “Arbutus Brands will add value to the entire Choom supply chain, from seed to sale. The synergies among our Choom companies will make for an extremely bright and exciting future as we approach the legalization of the recreational cannabis market in Canada .”

Transaction Highlights

The benefits of the Transaction for Choom include that it will:

Enable Choom to acquire SMP, which has submitted its AOR evidence package to Health Canada and expects to receive its cultivation license at any time;Create significant synergies in operational infrastructure and expertise across multiple disciplines to drive strong growth potential;Significantly improve and advance operational scale and production capacity; andStrengthen and accelerate Choom’s strategic direction as a fully-integrated cannabis company, representing a premiere lifestyle brand in Canada .

Specialty Medijuana Products Inc.

Continue reading
  0 Comments
0 Comments

Aphria Inc. (APHQF) Appoints Former Southern Glazer’s Executive Joel Toguri as Vice President of Sales

Aphria Appoints Former Southern Glazer’s Executive Joel Toguri as Vice President of Sales

Aphria Inc. (“Aphria” or the “Company“) (TSX: APH and US OTC: APHQF) today announced the appointment of Joel Toguri as Vice President of Sales effective on June 18, 2018 . Mr. Toguri joins the Company from Southern Glazer’s of Canada (“Southern Glazer’s“), where he was Vice President of Sales and Operations since 2013.

“We’re thrilled to bring Joel’s incredible talent and considerable experience to Aphria,” said Jakob Ripshtein, Chief Commercial Officer at Aphria. “Over many years, Joel has developed a proven track record of driving sales, generating growth and delivering results. His experience in building Southern Glazer’s in Canada and his deep familiarity with our exclusive sales distribution partner will help to ensure Aphria’s brands and products are successfully represented by cannabis retailers throughout the country.”

Mr. Toguri brings more than 20 years’ experience in the Canadian beverage alcohol industry. As Southern Glazer’s first employee in Canada , he was charged with establishing the company’s footprint throughout the country. He led a national sales team of more than 90 people and drove the company to become the #3 Agent/Broker in Canada in just three years. Prior to Southern Glazer’s, Mr. Toguri held leadership roles at MolsonCoors, Maxxium Wine & Spirits, and Beam Global Spirits & Wine.

“Aphria is amazingly well-positioned to capitalize on the opportunities in the adult-use market from coast to coast, right out of the gate,” said Mr. Toguri. “I am excited to be joining a true leader in the industry, and I look forward to continuing my close relationship with the dedicated team from Great North Distributors to drive the long-term success of Aphria and the Company’s portfolio of brands following legalization.”

We Have a Good Thing Growing.

Continue reading
  0 Comments
0 Comments

The Green Organic Dutchman Holdings Ltd. (TGOD.TO) (TGODF) Adds Additional 14,000 kg by Entering Jamaica Through Strategic Partnership

The Green Organic Dutchman Adds Additional 14,000 kg by Entering Jamaica Through Strategic Partnership With Epican Medicinals Ltd.

The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TGOD.TO) (TGODF) is pleased to announce it has entered into a strategic partnership with Epican Medicinals Ltd. This partnership will add an additional 14,000 kgs, taking TGOD’s total organic funded capacity to 130,000 kgs. Epican is a vertically integrated Jamaican cannabis company with cultivation, extraction, manufacturing and retail distribution licenses. This strategic partnership introduces TGOD’s premier organic cannabis brand to the international medical market.

“This represents the first of many strategic partnerships TGOD intends to execute in the coming months,” said Robert Anderson, CEO. “Our value-added approach taken in this investment will set an international M&A framework for capital investment, transfer of knowledge, and sector expertise. We will continue to evaluate international opportunities that will assist us in executing our business plan to become the world’s largest organic cannabis brand,” continued Anderson.

Epican produces high quality cannabis at its primary Blue Mountain cultivation site and has partnered with TGOD to construct a second 125,000 sq. ft. GMP compliant facility. Upon receiving the second site license, both facilities will cultivate high premium organic strains for the Jamaican and international markets. The Company will be working with Eco-Cert to achieve organic certification in Jamaica.

Epican’s extraction laboratory has been designed, licensed and built to GMP standards, establishing the company as a leader in sustainability with Jamaica’s Cannabis Licensing Authority (“CLA”). The company intends to sell a wide range of products such as dried flower, oils, pre-rolled joints, vapes, tinctures, among others. Epican’s initial offering of 11 scientifically formulated products will allow the company to service medical cannabis patients through its network of retail dispensaries (“Herb Houses”).

Jamaican dispensaries, known as Herb Houses, are crucial to the distribution of cannabis in Jamaica. Epican, with its first mover advantage, is opening its flagship dispensary in July 2018 located in Kingston, Jamaica. This will represent the first of many Herb Houses, with several more to be completed by the end of 2018 including locations along Jamaica’s northern coast. These locations will serve the medical needs of Jamaica’s 3 million residents and approximate 3.5 million visitors each year.

Continue reading
  0 Comments
0 Comments

Marijuana Stocks Newsletter – Thursday June 14, 2018

Good Morning & Happy Thursday! – 6/14/2018!

What’s The Next Big Wave For MJ?With Canada’s recreational MJ industy recently being legalized, cannabis stocks are captivating the markets. And if you’ve been following along, you would have already seen that one particular MJ Stock could be making a new trend and we’ve got the details for you, here.Read The Full Report

What Has Been Impacting Marijuana Stocks In 2018?The cannabis market throughout the world has seen a large amount of success in terms of implementation and legal measures, but many changes have yet to hit the market that are currently in development.Read The Full Article Here

How Is Marijuana Being Used As A Pain Management Drug

There is no doubt that there is a large amount of research showing the various positives surrounding the cannabis plant. With a large amount of medical studies currently being conducted, marijuana has been praised from a high level for its potential in everything from pain management to cancer treatment. Many users have been turning to cannabis to help deal with large amounts of pain, and the results are quite shocking.Read The Full Article Here

Continue reading
  0 Comments
0 Comments

PharmaCyte Biotech, Inc. (PMCB) Successfully Completes Another FDA Required Study

PharmaCyte Biotech Successfully Completes Another FDA Required Study Necessary for Submitting Investigational New Drug Application

PharmaCyte Biotech, Inc. (PMCB), a clinical stage biotechnology company focused on developing targeted cellular therapies for cancer and diabetes using its signature live-cell encapsulation technology, Cell-in-a-Box®, today announced that it has successfully completed the comprehensive characterization of its proprietary cell clone known as 22P1G.

The 22P1G cells constitute the cells in the Master Cell Bank (MCB) that were prepared and tested by PharmaCyte’s contractor, Eurofins Lancaster Laboratories. The cells from the MCB will serve as the active pharmaceutical ingredient (API) in the company’s Cell-in-a Box® capsules that will be used (together with low doses of the cancer prodrug ifosfamide) for the treatment of locally advanced, non-metastatic, inoperable pancreatic cancer (LAPC) in its planned clinical trial.

The comprehensive characterization studies include long-term stability of the cells, and stability of the potency of the cells as a therapeutic. All studies performed are required by the U.S. Food and Drug Administration (FDA).

PharmaCyte’s Chief Executive Officer, Kenneth L. Waggoner, elaborated on the significance of the studies saying, “PharmaCyte is complying with all of the FDA guidelines and recommendations for all cell tests and other recent studies with the 22P1G cells. Successful completion of these studies was a pre-requisite for the approval by the FDA for us to conduct a clinical trial in patients with LAPC. Our treatment is primarily dependent upon genetically engineered live-human cells that produce a particularly potent cytochrome P450 enzyme that can activate the chemotherapy prodrug ifosfamide (clone 22P1G cells).

Continue reading
  0 Comments
0 Comments

Plandaí Biotechnology, Inc. (PLPL) Discusses Cannabis Extract Opportunities and Research Potential

Plandai Biotechnology Discusses Cannabis Extract Opportunities and Research PotentialPlandaí Biotechnology, Inc. (OTCQB: PLPL) (“Plandaí” or “the Company”), producer of the highly bioavailable Phytofare® catechin complex, today discussed opportunities in the cannabis space and the Company’s efforts to develop the first and only full-profile, non-psychoactive cannabis extract.

Callum Cottrell-Duffield, Chief Operating Officer of Plandaí, released the following statement, “We are one hundred percent focused on getting a full-profile, non-psychoactive cannabis extract product to market.  We believe that with the synergies of the full cannabinoid profile, including the acid precursors of THC and CBD, the extract will yield a finished product with great consumer potential.  Prior research has demonstrated that cannabis, in its natural state, does not have psychotropic properties.  It is the process of heating and drying cannabis that metabolizes the THC-A and THC-B precursors into psychoactive THC.  Our extraction method, which relies of sonoluminescence instead of super-critical extraction, never introduces heat or drying into the process until after the molecules are stabilized.   The resulting product should provide the full potential of cannabis, not just CBD, but without the side effects.  In addition, we expect that our cannabis extract will demonstrate the same high levels of bioavailability as our other extracts, which have been clinically proven to have 15 times greater absorption in the blood stream over generic extracts.  We have the potential to produce an extremely powerful, full-profile, non-psychoactive cannabis product.”

Discussing the medical potential of the product, Mr. Cottrell-Duffield added, “Science is slowly beginning to research and understand the human endo-cannabinoid system.  This system helps modulate a variety of functions, including pain, memory, mood, and locomotor activity.  It is for this reason, we believe, that ingesting cannabis has been linked to improvements across a variety of neural-related problems such as controlling tremors, epilepsy, depression, and pain.  Once we have government approval in South Africa to commence producing our extract, our South African subsidiary plans to immediately establish a controlled-growing and extraction facility.  Our extract will then be thoroughly validated with respect to composition, bioavailability and non-psychoactivity.”

Mr. Cottrell-Duffield concluded, “We are convinced that consumers will gladly welcome a highly bioavailable full profile cannabis extract, that doesn’t come with any psychoactive side effects. We believe our extraction technology, in conjunction with our Phytofare Catechin Complex, that has been clinically shown to increase the bioavailability of plant catechins in the blood-stream for more than 24 hours, holds significant promise for a wide variety of  consumer based  products, especially as the legal and societal barriers to the acceptance of cannabis continue to fall by the wayside worldwide.”

About Plandai Biotechnology, Inc.

Plandai Biotechnology, Inc. (OTC Markets: PLPL) develops highly bioavailable, phytonutrient rich extracts which are being utilized to deliver a new family of drugs to safely and affordably treat a multitude of diseases and conditions. Plandai Biotechnology, through its South African subsidiaries, controls every aspect of production, from growing specific raw materials such as green tea on its farms to producing its proprietary Phytofare extract, allowing the Company to guarantee the continuity of supply as well as quality control throughout the entire process. The manufacturing facility has also been engineered for citrus fruits and the recovery of limonoids. Targeted industries for the Company’s products include animal husbandry, dietary supplements, diabetes and cannabis. Plandai Biotechnology is headquartered in London, United Kingdom. For more information, please visit: http://www.plandaibiotech.com

Continue reading
  0 Comments
0 Comments

The Supreme Cannabis Company, Inc. (SPRWF) Preparing for Growth as Cannabis Legalization Moves Forward

Supreme Cannabis Preparing for Growth as Cannabis Legalization Moves Forward Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on The Supreme Cannabis Company, Inc. (OTC PINK: SPRWF) is a Canadian publicly traded company, engaged into cultivation and distribution of sun-grown cannabis through its wholly-owned subsidiary 7ACRES. 7ACRES is a federally licensed producer of medical cannabis pursuant to the ACMPR operating inside a 342,000-sq. ft. Hybrid Greenhouse facility.

While many of the Canada based cannabis stocks have seen significant gains as Canadian legalization moves through the legislative process, Supreme shares are trading at the same level they were in early April.

Progress at the 7ACRES facility, new partnerships, analyst review and target READ MORE

Copy and paste to your browser may be required to view the report -https://tradersnewssource.com/supreme-cannabis/

In the recent past, the company’s operating and market profile has substantially benefited due to lucrative and growing Canadian cannabis market. Supreme focuses on executing on its B2B strategy in the cannabis space and intends to position 7ACRES as Canada’s leading brand for premium cannabis flower and leverage its perceived quality advantage by working with multiple re-sellers to capture the premium market segment.

During the nine months ending March 31, 2018, Supreme added multiple retail partners including International Herbs Medical Marijuana Ltd. d/b/a/ Zenabis, Terrascend Corp. d/b/a Solace Health, Puresinse Inc., and Potanicals Green Growers, Inc.

Continue reading
  0 Comments
0 Comments

Emblem Corp. (EMMBF) Making Smart Moves for Growth as Cannabis Legalization Moves Forward in Canada

Emblem Corp Making Smart Moves for Growth as Cannabis Legalization Moves Forward in CanadaTraders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Emblem Corp. (OTC PINK: EMMBF) is a licensed producer of medical cannabis under the Canadian Access to Cannabis for Medical Purposes Regulations.

On May 29th, the company reported financial and operating results for the first quarter ending March 31, 2018. Along with record sales and registered patient counts, EMMBF’s first quarter progressed rapidly in all areas (including market, operations, and financial flexibility) as the company focused on executing its multi-year plan.

EMMBF growth drivers, analyst review, and target READ MORE

Copy and paste to your browser may be required to view the report -https://tradersnewssource.com/emblem-corp/

Led by a team of cannabis experts and former healthcare and pharma executives, the Company has three distinct verticals – cannabis production, patient education centers, and pharmaceutical development.

Emblem is making strategic investments in pharmaceutical research and development, clinical research, marketing and promotion, product development and licensing.

Continue reading
  0 Comments
0 Comments

Future Farm Technologies Inc (FFRMF) Begins Build-out Process in Massachusetts

Future Farm Begins Build-out Process in Massachusetts and Completes Demolition Phase in Rhode Island

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (FFT.CN)(FFT.CN)(FFRMF) is excited to announce that the build out of its cultivation and extraction operation in Attleboro, Massachusetts has entered the next phase of development with the procurement of bids from general contractors.

Future Farm is also pleased to announce that it has completed the demolition of the interior of its Providence, Rhode Island building, which allows for the build-out of a cultivation facility to commence in earnest. The building is located in an M-1 zone, which legally permits the cultivation of cannabis by right. As previously announced, the Company intends to lease this property to a local, licensed cultivator who will use the property as a licensed medical marijuana cultivation space, providing wholesale cannabis to Rhode Island’s state-sanctioned dispensaries. Future Farm has already received a Letter of Intent to lease the property from a provisionally licensed cultivator and lease negotiations are currently underway.

Due to their geographic proximity to each other, Future Farm and its Rhode Island lessee have carefully curated these tandem efforts to maximize efficiencies and secure competitive pricing from vendors and suppliers. Chief project manager Derek Ross has accepted bids from four general contractors who are competing strongly to work on these high profile projects. The bids each represent local contractors, laborers and craftsmen.

“Southeastern Massachusetts and Providence, Rhode Island are traditionally underserved areas in the New England cannabis ecosystem,” says Mr. Ross. “We are now positioned to make a significant contribution to a part of the country struggling to keep up with supply demands, especially as Massachusetts progresses towards adult use and Rhode Island contemplates licensing twelve additional dispensaries, potentially leaving both states very unprepared from a supply perspective. We expect to change that landscape in a few short months.”

Continue reading
  0 Comments
0 Comments

CannaGrow Holdings, Inc. (CGRW) Announces Expansion of Colorado Buffalo Ranch Facility

CannaGrow Holdings Announces Expansion of Colorado Buffalo Ranch Facility

CannaGrow Holdings, Inc. (OTC PINK: CGRW) A Liaison and Consultant providing turnkey solutions to licensed growers — CannaGrow Holdings, Inc. announces NuGro Industries, Inc., Land Owner and Developer of the Colorado Buffalo Ranch Facility, has purchased an additional Olympia Steel Building, (https://www.olympiabuildings.com), for the installation of a new State-of-the-Art Post-Harvest Handling Facility.

Delmar Janovec, CEO, stated, “With the Buffalo Ranch Facility Phase I & II now operating at full capacity, the need for a standalone building dedicated to drying, curing, processing, and packaging has become increasingly apparent.  The licensed Grower, Category One Botanicals, LLC, has outperformed original projections and with all six climate-controlled Ranger Greenhouses operational, the Fall harvest alone is being conservatively estimated to exceed 900 pounds. This increase in product volume will stretch the limits of the current 400 sq. ft. Drying Room, so a 1,600 sq. ft. climate-controlled facility has been designed to meet current production as well as the future needs as Phase III, IV, & V infrastructure is built-out and in production.”

Dr. John P. Janovec, COO, added, “During the last 12 months, Licensed Grower Category One Botanicals has made great strides in dialing in the Colorado Buffalo Ranch Cultivation Facility & Protocols.  Their whole Flower products produced organically under sunshine combined with soil-based methods in state-of-the-art greenhouse environments have caught the eye of a growing list of buyers.  To meet the demand, production and harvest cycles in the Ranger Greenhouses will be perpetual beginning in June through late April of the following calendar year. During this time all greenhouse grow areas will be operating at full capacity. While the high-volume cultivation methods are streamlined and efficient, the drying and curing processes have met frequent bottlenecks primarily due to space constraints of the current drying room.  The addition of a state-of-the-art Post-Harvest Handling Facility will provide the space required to keep up with production volume and product demands.”

Rod Clawson, Managing Principle of Category One Botanicals, LLC, the licensed Grower, further commented, “I am pleased by the decision to add a drying, processing, and packaging facility to the Colorado Buffalo Ranch Facilities. It is a reasonable, logical next step in the development of one of the best organic grows in the State of Colorado, and it is another important milestone of the collaboration between the Land Owner and Developer, NuGro Industries, Inc., CannaGrow Holdings, Inc., the Manager of the Properties for the owner, and Category One Botanicals, LLC, the Licensed Grower.”

CannaGrow Holdings, Inc., the Liaison and Representative for NuGro Industries, will continue in its capacity of providing oversight as the Facilities Manager, working with the State/County Agencies and Category One Botanicals, LLC, the Licensed Grower for the facilities. The completion of this project will now provide the company the basis to begin generating revenues from Licensed Growers subleasing the Turnkey facilities being built to the specifications of CannaGrow COO, Dr. John P. Janovec, and Consultant, Jason Wells.

Continue reading
  0 Comments
0 Comments

Hemp, Inc. (HEMP) Signs Contract with HQ Global Education, Inc. to Plant 25 Acres of Hemp

Hemp, Inc. Signs Contract with HQ Global Education, Inc. to Plant 25 Acres of Hemp

Hemp, Inc. (OTC PINK: HEMP), a global leader in the industrial hemp industry with the largest multipurpose industrial hemp processing facility in the western hemisphere, announced today that Hemp, Inc. has signed a contract with HQ Global Education, Inc. (HQGE) to plant 25 acres of industrial hemp. The hemp, to be planted this month, will be grown and cultivated on land operated by Hemp, Inc. and is expected to yield 4,000 pounds of hemp per acre or a total 100,000 pounds of high cannabidiol (CBD) hemp biomass.  This is the first step in the collaboration between HQGE and Hemp, Inc. to grow premium hemp for the purpose of developing high quality CBD isolates and/or distillates and/or hemp-related products for Business-to-Business and possible Business-to-Consumer marketing.

Due to an increase of demand for high-quality CBD and hemp-related products, HQGE executives plan to contract a minimum of another 25 acres with Hemp, Inc. after the successful planting of the first 25 acres. This initial cultivation of hemp will be processed using Hemp, Inc.’s NuAxon Tech CO2 Supercritical Extractor which is housed in Hemp, Inc.’s 85,000-square foot facility in Spring Hope, North Carolina. Planting is expected to occur before the end of the month and should be ready for harvest by late August/early September 2018. The CBD extraction will begin immediately upon the harvesting and drying of the fully mature hemp harvest.

HQGE and Hemp, Inc. (HEMP) announced in March that they would be creating a joint venture between the two companies, in which HQGE will produce and distribute high-end, hemp-rich and highly customizable CBD formulas for the CBD industry using Hemp, Inc.’s NuAxon Tech CO2 Supercritical Extractor. Hemp, Inc. is also providing ongoing consulting services in the hemp-CBD market, specifically in the areas of growing high-quality organically-grown CBD-rich hemp, and harvesting, extracting and creating a variety of high-end CBD products.

“We look forward to furthering our relationship with HQGE as they expand their footprint in the hemp CBD market,” said Hemp, Inc. CEO Bruce Perlowin. “The CBD industry in the United States has enormous growth potential, especially as more states continue to legalize hemp and the proposed bill to legalize hemp at the federal level continues to gain bipartisan support.”

Dozens of master growers, from Oregon, Colorado, California, Kentucky, North Carolina, Nevada and, of course, Arizona, companies and organizations have also expressed an interest in pursuing a joint venture with Hemp, Inc. to each grow industrial hemp on the 300 fenced acres in Arizona as part of “The Great United American Hemp Project.” Interested master growers, from around the country, should contact Project Manager, Dwight Jory at .

Continue reading
  0 Comments
0 Comments

What Has Been Impacting Marijuana Stocks In 2018?

The cannabis market throughout the world has seen a large amount of success in terms of implementation and legal measures, but many changes have yet to hit the market that are currently in development.

The cannabis-research firm ArcView has stated that the legal cannabis market will likely grow at around a 26% rate year on year through 2021, where it is then expected to reach an even larger amount. Sales by 2021 are expected to hit somewhere in the ballpark of 22 billion, which makes the marijuana industry quite large when compared to others in similar fields. Because of the newness of the market and relative infancy, many investors have begun to flock into the market, resulting in a massive pool of money for companies to use to build their businesses throughout the coming years.

It has not bee uncommon in any way to see a marijuana stock this year double or triple in value, but we could potentially see these numbers going even higher into the next few years. Several factors have been affecting the industry, causing this large growth over the past year and it appears that there are still more factors to come into play regarding legislation and investments in the space.

The polling company Gallup has found that around 25% of U.S. residents in 1995 were in favor of having some sort of legalization for cannabis throughout the country. This number as of last year has more than doubled to as much as 64%, showing the massive amount of support nationwide for the cannabis industry. Many have been wondering as to what factors will affect the market this year, and there seems to be quite a few.

One of the most impending changes to the industry is the fact that Canada has worked to cement recreational legalization of cannabis on a nationwide level. This makes Canada the first developed nation to sell cannabis legally as a recreational substance. The bill has moved forward substantially and all that is needed now is the implementation of the new laws. The legalization of cannabis on this level will effectively help to bring in more foreign investors into the space, and will likely help to grow the cannabis industry to a larger level than ever before. The legal market in Canada has also benefitted from substantially lower taxes and prices than most legal markets, meaning that consumers will likely think twice before choosing to purchase cannabis on the black market.

Continue reading
  0 Comments
0 Comments

Medical Marijuana, Inc. (MJNA) Subsidiary HempMeds® Announces Import Permits for First-Ever THC-Free CBD Product in Argentina

Medical Marijuana, Inc. Subsidiary HempMeds® Announces Import Permits for First-Ever THC-Free CBD Product in Argentina

Medical Marijuana, Inc. (MJNA), the first publicly traded cannabis company in the United States, subsidiary HempMeds® today announced the historic authorization of its Real Scientific Hemp Oil-X (RSHO-X) cannabidiol (CBD) hemp oil product for import into Argentina. Argentina’s National Administration of Medicines, Food and Medical Technology (ANMAT) has approved the product for import.

“As a company of firsts, we’re proud to offer the first THC-free CBD product in Argentina,” said Medical Marijuana, Inc. CEO Dr. Stuart Titus. “In recent years, our company has been a leader in providing several Latin American countries with access to CBD and we’re happy to add this very important country to our roster.”

FLOS Innovation will be the exclusive distributor of RSHO-X in Argentina. This company is known for its dedication to high-quality offerings and product transparency.

“We’re very excited to partner with HempMeds and distribute these high-quality CBD products in our country,” said FLOS Innovation CEO Carlos Mendez. “We only work with the most reputable companies on the market and this company is no exception. We are very enthusiastic to help people understand the many therapeutic benefits of the product.”

In Argentina, CBD products are sold for compassionate use and must be prescribed by a licensed physician. A patient is allowed to import as much as a six-month’s supply and import is currently only allowed for the indication of refractory epilepsy. It is predicted that other conditions will soon be allowed.

Continue reading
  0 Comments
0 Comments

Future Farm Technologies Inc. (FFRMF) Provides Update on its Cannabis Breeding, Biochemistry and In-vitro Propagation Business Segment

Future Farm Provides Update on its Cannabis Breeding, Biochemistry and In-vitro Propagation Business Segment

Future Farm Technologies Inc. (the “Company” or “Future Farm”) (CSE: FFT) (OTCQX: FFRMF) is pleased to announce that its cannabis breeding and in-vitro propagation business segment (a joint venture with Rahan Meristem and CEPG, the “JV”) is vetting top candidates to fulfill the lead scientist role for its state-of-the-art laboratory in St. John’s, Newfoundland.

This move ushers in a new phase of planning and development for the space, slated to be completed in November of 2018. The objective for the JV is to position the Company as a research leader in genetics, biochemistry and in-vitro technology in the cannabis space. Research and development in St. John’s will help shape the future of cannabis research thought leadership while gaining valuable insight into propagation, cultivation and manufacturing. Additionally, this strategic JV is expected to create valuable IP to be sold worldwide, providing global reach on a scale thus far unrealized in the cannabis ecosystem.

Leveraging Rahan Meristem’s proprietary technology of non-GMO, in-vitro mutagenesis, Future Farm hopes to make significant strides in the medical applications of the plant.

“The future of agro-biotechnology as it relates to the cannabis plant is in its infancy. The top minds in their respective fields will help pave the way for powerful, ethical applications of this historically underutilized resource. Our strict vetting of top-tier geneticists will guide our vision of developing safe and valuable treatments, fulfilling clear and undeniable social imperative,” states Dr. Eli Khayat, biochemist and plant breeder, Vice President of Research and Development for Rahan Meristem.

Continue reading
  0 Comments
0 Comments

Reliq Health Technologies Inc. (RQHTF) Announces Six New Primary Care Physicians in Texas

Reliq Health Technologies Announces Six New Primary Care Physicians in Texas to Enroll up to 5,000 New Patients in iUGO Care Remote Patient Monitoring ProgramReliq Health Technologies Inc. (RHT.V) (RQHTF) (“Reliq” or the “Company”), a technology company that develops innovative mobile health (mHealth) and telemedicine solutions for the Community-Based Healthcare market, is pleased to announce that six new primary practices in Texas will add up to 5,000 new patients at full deployment to Reliq’s iUGO Care remote patient monitoring platform.

“We are excited to announce that we will be adding up to 5,000 new patients at full deployment from six primary care practices in the South Texas area to our iUGO Care platform,” said Dr. Lisa Crossley, CEO of Reliq Health Technologies, Inc. “We are expecting to receive our first shipment of our customers’ preferred monitoring devices in the next few weeks, at which point we will be able to resume onboarding patients for our existing customers and begin onboarding these new patients.  We look forward to continuing to help our customers deliver high quality virtual care to their patients in the home – reducing hospital admissions, improving health outcomes and enhancing patient and family satisfaction with their care.”

Reliq Health Technologies is a healthcare technology company that specializes in developing innovative software solutions for the Community Care market.  Reliq’s powerful iUGO Care platform supports care coordination and community-based healthcare.  The iUGO Care platform integrates wearables, sensors, voice technology and intuitive mobile apps and desktop user interfaces for patients, clinicians and healthcare administrators.  iUGO Care allows complex patients to receive high quality care at home, improving health outcomes, enhancing quality of life for patients and families and reducing the cost of care delivery.  iUGO Care provides real-time access to remote patient monitoring data, allowing for timely interventions by the care team to prevent costly hospital readmissions and ER visits. Reliq Health Technologies trades on the TSX Venture under the symbol RHT and on the OTCQB as RQHTF.

ON BEHALF OF THE BOARD“Dr. Lisa Crossley”CEO and Director

For further information contact:

Renmark Financial Communications Inc. Laura Welsh: : (416) 644-2020 or (514) 939-3989www.renmarkfinancial.com

Continue reading
  0 Comments
0 Comments

Tetra Bio-Pharma Inc. (TBPMF) Provides Corporate Update Ahead of Its Annual General Meeting

Tetra Bio-Pharma Inc. Provides Corporate Update Ahead of Its Annual General Meeting

Tetra Bio-Pharma Inc. (“Tetra” or the “Corporation”) (TSX VENTURE:TBP) (TBPMF), a global leader in cannabinoid-based drug development and discovery, is pleased to provide a Corporate Update on its programs and upcoming milestones in the development of its bio-pharmaceutical and natural health products that address large markets with significant unmet medical needs.

In Q3 of this year, TBP will file a request to commence a Phase 1 clinical trial for PPP004 our topical product indicated for General Neuropathic Pain, conservatively estimated as a billion-dollar market. Neuropathic pain can be caused by injury or disease and can be associated with such common conditions as shingles, diabetic neuropathy, multiple sclerosis, spinal stenosis and sciatica among other conditions.In Q3, we anticipate filing a request to commence a Phase 1 clinical trial for PPP003 an ocular treatment for eye pain and inflammation and dry eye.   The company has identified one lead compound that is a non-scheduled 1 cannabinoid which would significantly reduce time to market as is it not considered a controlled substance.  TBP is also exploring conducting a study focused on Dry-Eye, in the USA.Tetra-Bio-Pharma anticipates launching its Rx Oil capsules for the treatment of chronic pain and cancer pain in Q3 of this year.   The company is presently conducting a Phase IV study expected to be completed in Q3 and we expect the launch to occur in Q3.We expect to complete our Phase III trial for PPP001 in Q4/2018, Q1/2019 and will file for approval in Q1 of 2019. Tetra will seek additional indications for this product and we will announce our intentions soon.In Q3, we expect to launch our bioavailability study for PPP0002, and if we prove equivalence to the referenced product, Tetra anticipates filing for approval under the 505 (B) 2 route in the USA in Q4 2018.  In addition, Tetra expects to commence a Phase II study in chronic pain with PPP002 in Q3 of this year.Legalization of recreational cannabis is expected to take place in Q3/Q4 of this year following which Tetra Bio-Pharma will launch no fewer than 7 cannabinoid based Natural Health products in the Canadian market.  We will also look to license these products worldwide.

“Tetra Bio-Pharma has come a long way in the last 12 months and the momentum is building as we advance our products through various phases of clinical development, thereby answering the need for rigorous scientific evidence.  We believe our independently credentialed clinical development work, in combination with the launch of our natural health products will be instrumental in building shareholder value,” stated Guy Chamberland Interim CEO and CSO for Tetra Bio-Pharma.

About Tetra Bio-Pharma:

Tetra Bio-Pharma (TBP.V) (TBPMF) is a biopharmaceutical leader in cannabinoid-based drug discovery and development with a clinical program aimed at bringing novel drugs and treatments to patients and their healthcare providers. The Company has several subsidiaries that are engaged in the development of Bio Pharmaceuticals and Natural Health Products containing Cannabis and other medicinal plant-based elements. Tetra Bio-Pharma is focused on combining the traditional methods of medicinal cannabis use with the supporting scientific validation and safety data required for inclusion into the existing bio pharma industry by regulators, physicians and insurance companies.

More information at: www.tetrabiopharma.com

Continue reading
  0 Comments
0 Comments

Marijuana Stocks Newsletter – Wednesday June 13, 2018

Good Morning & Happy Wednesday! – 6/13/2018!

Choom (CHOO.CN) (CHOOF) Announces $10,000,000 Non-brokered Private Placement Lead By Aurora Cannabis Inc.Choom (CHOO.CN) (CHOOF) (the “Company”) is pleased to announce a non-brokered private placement for gross proceeds of up to $10,000,000 , including a $7,000,000 lead order from Aurora Cannabis Inc. The private placement will consist of up to 14,084,507 common shares at a price of $0.71 per share and is expected to close on June 18, 2018 .

Read The Full Article Here

What’s The Next Big Wave For MJ?With Canada’s recreational MJ industy recently being legalized, cannabis stocks are captivating the markets. And if you’ve been following along, you would have already seen that new highs have been hit nearly EVERY DAY for the last week with one particular MJ Stock and we’ve got the details for you, here.Read The Full Report

Blazing Past the Finish Line: How Marijuana Can Help Athletes

Continue reading
  0 Comments
0 Comments

How Is Marijuana Being Used As A Pain Management Drug

There is no doubt that there is a large amount of research showing the various positives surrounding the cannabis plant. With a large amount of medical studies currently being conducted, marijuana has been praised from a high level for its potential in everything from pain management to cancer treatment. Many users have been turning to cannabis to help deal with large amounts of pain, and the results are quite shocking.

Dr. Mark Ware has been studying the effects of cannabis on pain management for quite some time and believes that it could become one of the largest combatants of the opioid epidemic that the U.S. is currently facing. Ware states that in regard to their use when compared to opiates “The active ingredients in cannabis, THC, cannabidiol, really don’t appear to be good in acute pain settings. Where they do appear to play an important role is in chronic pain. When someone’s had pain for more than six months, there are some important changes in their spinal cord, in their brains. Receptors for cannabinoid molecules start to increase in number, and this makes people, we think, more responsive to potentially the analgesic effects of cannabinoids with chronic pain, and, in particular, pain which is caused by nerve injury — neuropathic pain.”

This type of research is still being conducted, but marijuana has shown that it can be a very solid treatment in many of the ways that opiates cannot. Additionally, cannabis has a low and almost non-existent amount of side effects depending on the individual, which cannot be said for its opiate counterpart. One of the newest ways to get pain relief from cannabis comes from the form of vaping. Ware states that it is “a very interesting technology that heats the plant to a temperature where the cannabinoid oils come off in a gas form but doesn’t burn the plant material and therefore have some of the nasty side effects of inhaling burnt smoke. And then, of course, there are oral administrations, so especially here in Canada where our legal industry is producing oils where they extract the cannabinoids from the plant into an oil base, and that can be taken in food or under the tongue.” The oils that Ware is referring to have become a large part of the industry as well, and have become one of the main choices for those looking for pain management in the marijuana field.

Ware goes on to state that doctors need to be looking into ways that they can treat their patients using cannabis since it has shown itself to be such an effective treatment for so many different ailments. One of the issues with prescribing cannabis, however, is the fact that not only do doses of the psychoactive components vary, but these components affect every person differently depending on a whole variety of factors. Because of this, it can often be difficult to gauge how much of the substance a user is taking, and thus difficult to find an appropriate dose. This is quickly changing however with the new world of edibles and oils, where the doses are becoming much more accurate and exact.

Marijuana has been used for thousands of years as a treatment for many different ailments that we come into contact with every day. New research is continuing to be done on how cannabis can help to treat all types of diseases and pain types, but for now, this research is still largely underway. The hopes are high that the future of cannabis will include new and accurate ways to use the substance for a wide range of medical conditions.

Continue reading
  0 Comments
0 Comments

Choom™ (CHOO.CN) (CHOOF) Announces $10,000,000 Non-brokered Private Placement

Choom Announces $10,000,000 Non-brokered Private Placement, Secures Aurora Cannabis as $7,000,000 cornerstone investor

Choom (CHOO.CN) (CHOOF) (the “Company”) is pleased to announce a non-brokered private placement for gross proceeds of up to $10,000,000 , including a $7,000,000 lead order from Aurora Cannabis Inc.  The private placement will consist of up to 14,084,507 common shares at a price of $0.71 per share and is expected to close on June 18, 2018 .

“We are delighted to have the confidence and support of one of the world’s leading cannabis companies as we move forward with our retail cannabis strategy,” states Chris Bogart , President and CEO of Choom. “With the legalization of adult use cannabis in Canada on track, Choom is positioning itself to be one of the leading premium choice brands for Canadian consumers. This investment by Aurora accelerates our corporate strategy of delivering a true seed to sale experience through an offering of high quality cannabis to Canadian consumers across the country.”

“Our investment in a consumer-focused brand with a strong retail strategy offers Aurora additional growth opportunities through supply, retail and distribution to the adult consumer use market, once legalized,” said Terry Booth , CEO of Aurora. “We’re excited to strengthen our relationship with the team at Choom and help amplify their market reach as they continue to execute on their differentiated craft growing philosophy and their unique retail strategy.”

The placement is being made under applicable exemptions from prospectus requirements and may include one or more subscriptions by insiders and other existing shareholders of the Company.  A portion of this placement may be subject to finder’s compensation or commissions.  All of the securities issued in connection with the placement will be subject to a four month hold period under securities laws.

None of the securities issued in connection with the placement will be registered under the United States Securities Act of 1933, as amended (the “1933 Act”), and none of them may be offered or sold in the United States absent registration or an applicable exemption from the registration requirements of the 1933 Act. This news release shall not constitute an offer to sell or a solicitation of an offer to buy nor shall there by any sale of the securities in any state where such offer, solicitation, or sale would be unlawful.

Continue reading
  0 Comments
0 Comments

America Places Mary Jane in the Friendzone: Influential Politicians Backing Marijuana Isn’t Enough

Yes, no, maybe. These mixed signals are familiar to any American on this traumatic, post-digital dating scene, but now they’re getting the slip from Congress too. Lawmakers are giving everyone, from pot smokers to industry officials and scientists, whiplash with their conflicting responses to the ongoing marijuana legalization debate. In 2017, Vermont Gov. Phil Scott vetoed legalization after it had already been approved. More than half of US states permit the use of marijuana in some form, whether it’s medicinal or recreational. Important officials have backed the drug across political parties, but it isn’t enough. On Friday, President Trump revealed he is in favor of bipartisan efforts to lift the federal ban on cannabis. So, what is keeping the red, white, and blue from turning full-on green?

With the current federal ban in place, the penalties for marijuana use are a bit muddled. It is currently classified as a Schedule 1 drug, ranking on the same level as LSD and heroin. In January, the Justice Department withdrew the Cole memo which was enacted by former President Obama. This policy protects cannabis businesses in states where the drug is legal. This act sent sellers into a frenzy as they were warned by prominently opposed Attorney General Jeff Sessions that they might be targeted by prosecutors. Things were looking bleak for marijuana advocates until President Trump swooped in and ordered an end to this before it ever really got off the ground. There have yet to be raids or seizures of companies in states where the drug has been legalized in some form. Despite pleadings from several narcotics officer groups, Trump has said that he is most likely going to support legislation that will allow states to make their own decisions within their borders about marijuana. They will, however, be required to obey the federal restrictions and not sell to anyone under the age of 21 years old who is not using the hemp plant for medicinal purposes.

Consumers would assume that having the president publicly declare his support for the hemp plant would put it on top of the world, but his backing and that of other influential lawmakers isn’t enough. Conservative politicians are continuing to drag their feet. The bipartisan efforts aim to modify the Controlled Substances Act and reassure the anxious cannabis industry, but they are being met with tough resistance. Many believe that President Trump’s remarks are to be taken lightly because of his past with pushing legislation, but many marijuana advocates are thrilled to have this reinforcement on their side. Working as one of the lead sponsors on the bill is Sen. Corey Gardner of Colorado. The legislation would ease concerned bankers. Under it, sellers would not be subject to penalization, raids, or seizures as their transactions as long as they concede to their state’s laws and restrictions.

Using history as a model, ending cannabis prohibition would decrease nationwide crime. In January of 1920, when alcohol prohibition led to bootleggers and moonshine, mobsters and crime lords plagued neighborhoods and took control. Crime rates soared and the ban on alcohol generated even bigger problems than they were faced with in the first place. Today, more and more people are being incarcerated for marijuana-related crimes. In 2016, almost 600,000 adults were jailed for cannabis. That is more than all the people incarcerated for violent crimes, such as rape and murder, combined. And law enforcement continues to make a staggering amount of arrests for the drug today. This means that massive portions of the criminal justice system’s budget are allocated towards sentencing and prosecuting marijuana users. According to ThoughtCo.com, the American government would save an estimated $8 billion in law enforcement spending with legalization. Conservatives have cited legalization as encouragement for increased drug use, and claim they do not want to be perceived as being “easy” on drugs, for their reluctance.

Marijuana is one of America’s leading capita-generating crops. According to the Colorado Department of Revenue, the plant has raked in over $4.5 billion for the state since its legalization. If the bill to allow states to legalize without fear of federal prosecution goes into law, this number would skyrocket for the entire nation. Creating a new market opportunity available for trading in foreign markets like Canada is gearing itself up for. According to Gallup surveys, 60 percent of American voters are in favor of ending prohibition, but politicians continually come in to block their efforts. Even with numbers, the public’s opinion, and influential politicians on its side, it seems that even the president’s backing isn’t enough. The controversial battle over marijuana is a balancing act whose scales are constantly being tipped in either direction. Currently, persuasion to back this bill is slowly gaining momentum in Congress.

Continue reading
  0 Comments
0 Comments

Blazing Past the Finish Line: How Marijuana Can Help Athletes

Olympic swimmer Michael Phelps is a household name, but in 2009 the “son of Poseidon” was making headlines for an entirely different reason. A British tabloid printed a photo of Phelps appearing to be smoking marijuana from a bong at the University of South Carolina. This scandal emerged mere months after his exhilarating victory at the Beijing Olympics, in which he won eight gold medals, and resulted in a three-month-long suspension for Phelps. Controversies aside, marijuana can actually help athletes.

This is not an isolated incident. Ross Rebagliati of Canada was stripped of the snowboarding gold medal in 1998 after his urine tested positive for tetrahydrocannabinol, or THC. This is the part of marijuana that gets users high. Though he appealed and was later given back his medal, the stigma remained. In recent years, the culture surrounding marijuana has undergone a dramatic change. People typically don’t bat an eyelash to marijuana usage and while it is still officially prohibited for Olympians, studies have shown that the drug does have certain benefits for training athletes. The World Anti-Doping Agency (WADA) says athletes must have less than 150 nanograms per millimeter of carboxy-THC in their urine, common workplace drug tests cap their limits between 15 ng/mL to 100 ng/mL. While the discussion of whether marijuana can be considered a performance-enhancing drug is one for debate, the science behind it is clear. Because scientists have turned to marijuana to help people suffering from cancer and epilepsy, among other conditions, they have also been able to further delve into the hemp plant and explore its effects on the body.

Marijuana is already being prescribed to patients in states where its medicinal use has been legalized as a painkiller and anti-inflammatory. These benefits of cannabidiol, or CBD, are clear for athletes whose tired muscles come back aching and swollen from spending 30-40 hours a week in the gym. CBD is the nonintoxicating part of marijuana. It is being broadly hailed in recent years for it healing properties. Using marijuana can decrease recovery time and get athletes in the gym quicker and for longer. When working out, athletes create tiny tears in their muscles that lead to soreness. The tears are repaired over time which increases muscle mass and strength. By reducing this feeling of soreness, athletes feel better when getting back into the gym and perform better. And because WADA ended its ban of CBD in 2017, many of these athletes are able to take advantage of the drug’s effects. WADA warns athletes to use CBD sparingly because consuming too much of it could cause there to be an increase in THC in their urine. Additionally, CBD extracted directly from the hemp plant could contain different levels of THC. If not monitored, athletes could accidentally go over the allowed THC limit, which would result in a positive drug test and their suspension or expulsion from the Olympics and other consequences.

Smoking is not the only way for athletes to get CBD into their systems and reap the rewards of this controversial drug. Because people have begun exploring the hemp plant more, there are various ways to consume it. People have pioneered hemp skin care products, baked goods, beverages, oils, vitamins, and so on and so forth. The endocannabinoid receptors are present throughout the body and are susceptible to any of these products. CBD’s properties have mental benefits for athletes as well as the physical. They can help calm anxious athletes before an important match or performance and help them focus and get into the frame of mind necessary to win. Many marathon runners are even coming out to admit that marijuana has helped them keep up endurance. In a world where athletes are expected to perform at superhuman rates, it is important to be aware of all the options open to them.

Photo Credit: Perre-Philippe Marcou/AFP/Getty

The post Blazing Past the Finish Line: How Marijuana Can Help Athletes appeared first on Marijuana Stocks | Cannabis Investments and News. Roots of a Budding Industry.™.

Original link
  0 Comments
0 Comments

Marijuana Stocks Tuesday Morning Newsletter – June 12, 2018

Good Morning & Happy Tuesday! – 6/12/2018!

What’s The Next Big Wave For MJ?With Canada’s recreational MJ industy recently being legalized, cannabis stocks are captivating the markets. And if you’ve been following along, you would have already seen that new highs have been hit nearly EVERY DAY for the last week with one particular MJ Stock and we’ve got the details for you, here.Read The Full Report

The Ties Between the U.S. Cannabis Market and the Canadian Marijuana IndustryThe legal status of cannabis in the U.S. is still extremely difficult to decipher and looks as though it could be changing shortly. This has left a large amount of room for other markets to develop such as the large industry in Canada. There is a large amount of room to grow given the legal issues in the U.S., but many companies have decided to forgo the waiting and move their companies up north. This has meant that a large amount of U.S. companies have been listing throughout various Canadian stock exchanges as opposed to domestic listings.Read The Full Article Here

U.S. Government Talks Further About Marijuana Legalization

The state of cannabis in the U.S. has been in quite a topsy-turvy area for some time now, with a battle between states fighting for marijuana legislation and the government denying it or at least turning an eye to the legalization. In a note made on Friday, June 8th, Jeff Sessions stated that he had missed an invite to discuss moving forward with marijuana legislation in a meeting with Senator Cory Gardner and President Donald Trump.Read The Full Article Here

Continue reading
  0 Comments
0 Comments